• In April 2026, Guardant Health announced a multi-year collaboration with Nuvalent to use its Guardant Infinity platform’s tissue and liquid biopsy tests in supporting Nuvalent’s global oncology trials and potential commercialization efforts.
• This alliance highlights how pairing Nuvalent’s kinase-targeted cancer therapies with Guardant’s precision diagnostics could tighten patient selection, streamline regulatory pathways, and strengthen future companion diagnostic strategies.
• Next, we’ll examine how embedding Guardant’s companion diagnostics into Nuvalent’s clinical programs may influence the company’s longer-term investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Nuvalent's Investment Narrative?

For Nuvalent, the core belief you’d need as a shareholder is that its precision oncology pipeline can translate into approved drugs and a sustainable business before cash constraints or clinical setbacks bite. The near term story still revolves around regulatory milestones for zidesamtinib and neladalkib, plus how ongoing trial readouts shape expectations for a company that currently has no revenue and sizeable annual losses of about US$425,377,000. The Guardant Health collaboration slots directly into those catalysts by potentially sharpening patient selection and giving Nuvalent a clearer path to companion diagnostics if its drugs are approved. That said, the alliance does not change the fundamental risks around binary FDA decisions, future financing needs after the 2025 equity raise, and the possibility that key trials do not produce the data regulators want.

However, there is one funding-related risk investors should not overlook. Despite retreating, Nuvalent's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

With just 1 fair value estimate from the Simply Wall St Community pointing to a very large gap above the current share price, you are seeing how individual views can strongly disagree with market pricing. Set against the clinical and regulatory milestones and the Guardant Health collaboration discussed earlier, this divergence underlines how much future trial outcomes and FDA decisions could reshape expectations for Nuvalent’s performance.

Explore another fair value estimate on Nuvalent - why the stock might be worth just $590.46!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nuvalent research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Nuvalent research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nuvalent's overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.